Nonresponse to Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Cell Carcinoma of the Bladder

作者：Mossanen Matthew^*; Lee Franklin; Cheng Heather; Harris William; Shenoi Jaideep; Zhao Song; Wang Junfeng; Champion Thomas; Izard Jason; Gore John L; Porter Michael P; Yu Evan Y; Wright Jonathan L

来源：Clinical Genitourinary Cancer, 2014, 12(3): 210-213.

DOI：10.1016/j.dgc.2013.10.002

• Cisplatin
• Cystectomy
• Muscle-invasive
• Nonresponse
• Urothelial cell cancer

Neoadjuvant chemotherapy (NC) is routinely used in the treatment of muscle-invasive bladder cancer. In this retrospective study, patient characteristics and rates of failure to respond to NC were identified. In 5 patients, 1 did not respond to NC. Nonresponse was more common among patients who received non-cisplatin-based NC regimens and elderly patients.
Background: Cisplatin-based neoadjuvant chemotherapy (NC) is commonly used in the treatment of muscle-invasive urothelial cell carcinoma of the bladder (UC) and has been shown to improve survival. However, not all patients respond to NC, thus delaying the interval to potentially curative surgical therapy, risking disease progression and subjecting patients to potential morbidity from NC. In this study, we perform a retrospective analysis of patients who received NC prior to cystectomy to identify factors associated with nonresponse.
Patients and Methods: We identified 80 patients with clinical T2 to T4, N0 to N1 UC of the bladder who received NC and underwent radical cystectomy. Nonresponse was defined as patients with higher pathologic T stage than clinical stage or patients with nodal involvement identified on final pathology.
Results: Overall, 20% of patients were considered nonresponders. In multivariate analysis, age was predictive of nonresponse (P-trend < .05). Compared with those < 60 years of age, those aged 60 to 69 years (odds ratio [OR], 2.9; 95% CI, 0.7-12) and those aged >= 70 (OR, 5.0; 95% CI, 0.9-28) had higher odds of nonresponse. Patients who received gemcitabine-carboplatin had higher odds of nonresponse compared with those who received gemcitabine-cisplatin (OR, 4.4; 95% CI, 0.8-21).
Conclusion: A subset of patients receiving NC prior to cystectomy will experience disease progression. Future study will need to better identify methods to distinguish individuals more likely to benefit from NC and those that should receive upfront cystectomy.

• 出版日期2014-6